1-12 of 12
stromal neoplasm
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Generation and Application of T-Cell Lymphoma Patient Derived Tumor Xenograft Models

Danilo Fiore, PhD, Xujun Wang, Inna Khodos, Filomena Di Giacomo, PhD, Marcello Gaudiano, BS, Jude M Phillip, DPhil, Rui Wang, Zhiwei Yang, Michael Ginsberg, Andrew M Intlekofer, MD PhD, Craig B. Thompson, MD, Jon C. Aster, MD PhD, Jia Ruan, MD PhD, Samuel Y. Ng, MDPhD, Eric Jacobsen, MD, Ahmet Dogan, MD PhD, Elisa de Stanchina, Marissa Mattar, Leandro Cerchietti, MD, Rohan Bareja, Olivier Elemento, PhD, Wayne Tam, MD PhD, David M. Weinstock, MD, Shahin Rafii, MD, Steven M. Horwitz, MD, Giorgio Inghirami, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 109.
https://doi.org/10.1182/blood.V130.Suppl_1.109.109
Published: 2017
Journal Articles

Myeloid Malignancies Following Luminal Gastrointestinal Cancer: High Incidence of Deletion 5q and DNTM3A Mutations

Zachary D. Epstein-Peterson, MD, Sean M. Devlin, PhD, Eytan M. Stein, MD, Virginia M. Klimek, MD, Leonard B. Saltz, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1309.
https://doi.org/10.1182/blood.V130.Suppl_1.1309.1309
Published: 2017
Journal Articles

Clinical Significance of Ck2 (CSNK2) and C-Myc Expression in Childhood Acute Lymphoblastic Leukemia

Paola Bonaccorso, Manuela La Rosa, Nellina Andriano, Valeria Iachelli, Emanuela Cannata, MD, Francesco Bellia, MD, Marinella Licciardello, MD PhD, Andrea Di Cataldo, MD PhD, Giovanna Russo, MD PhD, Luca Lo Nigro, MD, PhD
Journal: Blood
Blood (2016) 128 (22): 5269.
https://doi.org/10.1182/blood.V128.22.5269.5269
Published: 2016
Journal Articles

Preclinical Characterization of PWT143, a Novel Selective and Potent Phosphatidylinositol 3-kinase Delta (PI3K delta) Inhibitor with Ex-Vivo Activity in Hematologic Malignancies.

Marie O'Farrell, PhD, Richard Ventura, Albert Tai, Jeffrey W Tyner, PhD, Marc M Loriaux, MD, PhD, Daruka Mahadevan, MD, PhD, Carla Morales, S. David Brown, David J Matthews, PhD
Journal: Blood
Blood (2012) 120 (21): 2907.
https://doi.org/10.1182/blood.V120.21.2907.2907
Published: 2012
Journal Articles

Stromal Tumor Microenvironment in CLL: Regulation of Leukemic Progression

Nagendra K Chaturvedi, PhD, Adam K Ahrens, BA, Ashima Shukla, BS, Christine E Gilling, BS, Amit K. Mittal, PhD, DVM, MS, Philip Bierman, MD, Dennis D Weisenburger, MD, Runqing Lu, PhD, Shantaram S Joshi, PhD
Journal: Blood
Blood (2012) 120 (21): 1781.
https://doi.org/10.1182/blood.V120.21.1781.1781
Published: 2012
Journal Articles

Effect of the Tyrosine Kinase Inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) On Blood Glucose Levels in Diabetic and Non-Diabetic Patients.

Nicole M. Agostino, DO, Vernon M Chinchilli, PhD, Anita Koszyk-Szewczyk, MD, Rebecca Gingrich, RN, MS, OSN, Jeff Sivik, PharmD, Joseph Drabick, MD
Journal: Blood
Blood (2009) 114 (22): 4265.
https://doi.org/10.1182/blood.V114.22.4265.4265
Published: 2009
Journal Articles

FIP1L1-PDGFRα D842V, a Novel Panresistant Mutant, Emerges after Treatment of FIP1L1-PDGFRα T674I Eosinophilic Leukemia with Single Agent Sorafenib

Peter Vandenberghe, MD, PhD, Els Lierman, Lucienne Michaux, MD, PhD, Pascal Pierre, MD, Peter Marynen, PhD, Jan Cools, PhD
Journal: Blood
Blood (2008) 112 (11): 3730.
https://doi.org/10.1182/blood.V112.11.3730.3730
Published: 2008
Journal Articles

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Andrew J. Lurie, BGS, Mark V. Mai, Martin S. Tallman, MD, June McCoy, MD JD MPH, Charles L. Bennett, MD PhD MPP
Journal: Blood
Blood (2006) 108 (11): 3318.
https://doi.org/10.1182/blood.V108.11.3318.3318
Published: 2006
Journal Articles

Imatinib Mesylate-Induced Complete Cytogenetic Response in Acute Myeloid Leukemia with t(5;12)(q33;p13).

William Blum, MD, Guido Marcucci, MD, Hollie Devine, CNP, Rebecca Klisovic, MD
Journal: Blood
Blood (2006) 108 (11): 4414.
https://doi.org/10.1182/blood.V108.11.4414.4414
Published: 2006
Journal Articles

FLT3 and KIT Mutated Pediatric Acute Myeloid Leukemia (AML) Samples Are More Sensitive In Vitro to the Tyrosine Kinase Inhibitor SU11657.

Bianca F. Goemans, MD, Christian M. Zwaan, MD,PhD, Desiree de Lange, Jacqueline Cloos, PhD, Dirk Reinhardt, MD,PhD, Karel Hahlen, MD,PhD, Brenda E.S. Gibson, MD,PhD, Ursula Creutzig, MD,PhD, GertJan J.L. Kaspers, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 1359.
https://doi.org/10.1182/blood.V108.11.1359.1359
Published: 2006
Journal Articles

Thalidomide-Associated Thromboembolism in Cancer: Reimbursement for Thalidomide’s “Off-Label” Prescribing under the 2004 Medicare Oral Pharmaceutical Demonstration Project Raises Concerns.

Andrew M. Evens, DO, MS, June M. McKoy, MD, MPH, JD, Paul R. Yarnold, PhD, Kathyrn McCaffrey, BA, Charles L. Bennett, MD, PhD, MPP
Journal: Blood
Blood (2005) 106 (11): 2244.
https://doi.org/10.1182/blood.V106.11.2244.2244
Published: 2005
Journal Articles

BMS-354825 Potently Inhibits the Kinase Activity of KIT Activation Loop Mutations Associated with Systemic Mastocytosis and Induces Apoptosis of Mastocytosis Cell Lines.

Marcus Schittenhelm, M.D., Sharon Shiraga, Francis Y. Lee, Ph.D., Michael C. Heinrich, M.D.
Journal: Blood
Blood (2004) 104 (11): 2424.
https://doi.org/10.1182/blood.V104.11.2424.2424
Published: 2004